Suzhou Deneugen Biotechnology

Suzhou Deneugen Biotechnology (also known as Suzhou Dixinchenke Biotechnology) is a clinical-stage biopharmaceutical company focused on the research, development, and clinical translation of recombinant neurotoxin-based therapeutics. Founded in 2022 and based in the Suzhou Industrial Park, China, the company leverages recombinant protein technology to develop next-generation botulinum toxin products with improved safety, purity, and efficacy profiles. Its lead candidate, DN001 (a recombinant botulinum toxin type A), is currently in Phase 1/2 clinical development for the treatment of moderate-to-severe glabellar frown lines. Additionally, the company is advancing DN002, a recombinant botulinum toxin lyophilized powder, which entered Phase 1 clinical trials in late 2026 for the treatment of cervical dystonia.